biote Corp. Price & Performance (BTMDW)

Biote Corp delivered a strong Q1 2025, posting $0.37 EPS—well above analyst forecasts—and $49 million in revenue, aided by a 25.5% jump in dietary supplement sales. The stock jumped over 10% in aftermarket trading, reflecting renewed investor confidence despite ongoing restructuring and competitive pressures in the hormone optimization market.123

Following Biote Corp’s Q1 results, analysts raised earnings estimates for 2025, now projecting $0.64 EPS, though revenue growth is expected to slow to 2.7%. Price targets have been trimmed, with consensus falling to $7.00, as the company’s expansion lags industry peers despite the recent profitability boost.456

Biote Corp shares gained nearly 7% last Friday, buoyed by increased trading volume and positive technical indicators. The stock has risen 16.6% over the past two weeks, with both short- and long-term moving averages signaling further upside potential. Support is seen at $3.76, though volatility remains moderate.78